Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia

Matsumaru,Aki; Tsutsumi,Yutaka; Ito,Shinichi

doi:10.3892/mco.2017.1350

Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia

Authors:
- Aki Matsumaru
- Yutaka Tsutsumi
- Shinichi Ito
View Affiliations

Affiliations: Department of Outpatient Chemotherapy Center, Hakodate Municipal Hospital, Hakodate, Hokkaido 041-0821, Japan, Department of Hematology, Hakodate Municipal Hospital, Hakodate, Hokkaido 041-0821, Japan
Published online on: July 28, 2017 https://doi.org/10.3892/mco.2017.1350
Pages: 629-632

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy-induced nausea and vomiting has a considerable negative impact on the quality of life of patients with cancer. Unfortunately, there has been little progress in the development of supportive therapies for the anti-emetic treatment of patients with hematopoietic tumors. This lack of supportive treatments motivated the present retrospective comparison between two groups of anti-emetic drugs. The current study aimed to compare granisetron and palonosetron in order to determine which is more effective, based on cases of patients undergoing remission induction therapy and consolidation therapy for the treatment of acute myeloid leukemia. Granisetron or palonosetron were administered in Japanese-approved dosages (3 mg granisetron once per day for 5 or 7 days, or one administration of 0.75 mg palonosetron). Patients were randomly selected, and their clinical information was acquired from medical records. The data represent the doctors' and nurses' records. The results demonstrated that palonosetron treatment (in which the drug was administered alone or in combination with aprepitant) was more effective than granisetron treatment for the complete control of acute vomiting. Therefore, in the treatment of hematopoietic malignancies, palonosetron is an effective regimen to be administered alongside more than 5 continuous days of anti-cancer agents. Furthermore, the combination of palonosetron and aprepitant was found to be the optimal combination. In conclusion, palonosetron is superior to granisetron for the prevention of nausea and vomiting induced by chemotherapy for hematological cancers. In Japan, the standard dose of palonosetron is 0.75 mg; a dose of 0.25 mg of palonosetron must be compared with 0.75 mg in future studies.

View Figures

View References

1	Cohen L, de Moor CA, Eisenberg P, Ming EE and Hu H: Chemotherapy-induced nausea and vomiting: Incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 15:497–503. 2007. View Article : Google Scholar : PubMed/NCBI
2	Hori K, Kobayashi N, Atsumi H, Nagayama A, Kondoh M, Noge I, Kimura M, Utsugi H, Iwasaki T, Nakamura M, et al: Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: A nationwide survey using a distributed research network. Support Care Cancer. 22:969–977. 2014. View Article : Google Scholar : PubMed/NCBI
3	Rojia F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al: Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting:results of the Perugia consensus conference. Ann Oncol. 21 Suppl 5:232–243. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, et al: American Society of Clinical Oncology: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol. 24:2932–2947. 2006. View Article : Google Scholar : PubMed/NCBI
5	Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, et al: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 17:1441–1449. 2006. View Article : Google Scholar : PubMed/NCBI
6	Kris MG, Tonato M, Bria E, Ballatori E, Espersen B, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Saito M, et al: Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer. 19:S25–S32. 2011. View Article : Google Scholar : PubMed/NCBI
7	Botrel TEA, Clark OAC, Clark L, Paladini L, Faleiros E and Pegoretti B: Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: Systematic review and meta-analysis. Support Care Cancer. 19:823–832. 2011. View Article : Google Scholar : PubMed/NCBI
8	Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, et al: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with Plonosetron, a pharmacollogically novel 5-HT3 receptor antagonist. Cancer. 1:2473–2482. 2003. View Article : Google Scholar
9	Yang LPH and Scott LJ: Palonosetron: In the prevention of nausea and vomiting. Drugs. 69:2257–2278. 2009. View Article : Google Scholar : PubMed/NCBI
10	Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, et al: Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 107:469–478. 2008. View Article : Google Scholar : PubMed/NCBI
11	Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R, Goto K, Takiguchi T, Ohyanagi F, Kogure Y, et al: Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol. 27:1601–1606. 2016. View Article : Google Scholar : PubMed/NCBI
12	Navari RM: Pharmacological management of chemotherapy-induced nausea and vomiting: Focus on recent developments. Drugs. 69:515–533. 2009. View Article : Google Scholar : PubMed/NCBI
13	Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S and Slusher BS: Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 626:193–199. 2010. View Article : Google Scholar : PubMed/NCBI
14	Saito M and Tsukuda M: Review of palonosetron: Emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 11:1003–1014. 2010. View Article : Google Scholar : PubMed/NCBI
15	Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T and Mitsuhashi S: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 10:115–124. 2009. View Article : Google Scholar : PubMed/NCBI
16	Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD and Cox D: Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 22:469–477. 2014. View Article : Google Scholar : PubMed/NCBI
17	Phase I clinical trial of granisetron(part2)-Pharmacokinetics at the time of single and repeated intravenous administration. Rinsho Iyaku Jpn. 6:(suppl-5). 25–34. 1990.
18	Maemoto M, Tsukuda M, et al: A PhaseIIstudy of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann Oncol. 20:1874–1880. 2009.PubMed/NCBI
19	Hothersall JD, Moffat C and Connolly CN: Prolonged inhibition of 5-HT receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization. Br J Pharmacol. 169:1252–1262. 2013. View Article : Google Scholar : PubMed/NCBI
20	Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, et al: Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study. Cancer Med. 4:333–341. 2015. View Article : Google Scholar : PubMed/NCBI
21	Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, et al: American Society of Clinical Oncology: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 29:4189–4198. 2011. View Article : Google Scholar : PubMed/NCBI